This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
BioMarin Stops Voxzogo Development for Noonan Syndrome
by Zacks Equity Research
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
BMRNPositive Net Change ASNDPositive Net Change BBIONegative Net Change
biotechs medical
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
by Sundeep Ganoria
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
ABBVNegative Net Change BIIBNegative Net Change JNJPositive Net Change
biotechs medical pharmaceuticals
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
CNMDPositive Net Change GMEDPositive Net Change VCYTNegative Net Change INSPNegative Net Change
medical medical-devices
Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?
by Indrajit Bandyopadhyay
Cardinal Health expects IRA pricing changes to pressure Pharma revenues while protecting profitability through compensation and durable distribution agreements.
CAHNegative Net Change CVSNegative Net Change BTSGPositive Net Change
medical medical-devices
Is the Options Market Predicting a Spike in Ardent Health Stock?
by Zacks Equity Research
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
ARDTPositive Net Change
medical
GEHC Launches CareIntellect AI Tool to Optimize Hospital Operations
by Zacks Equity Research
GE HealthCare launches an AI-powered SaaS tool that predicts hospital capacity challenges up to 72 hours ahead and recommends actions to ease bottlenecks.
GEHCNegative Net Change GMEDPositive Net Change VCYTNegative Net Change INSPNegative Net Change
medical medical-devices
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
by Zacks Equity Research
Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.
ISRGPositive Net Change WSTNegative Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
Here's Why You Should Add Avantor Stock to Your Portfolio for Now
by Zacks Equity Research
AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.
AVTRPositive Net Change WSTNegative Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
by Zacks Equity Research
IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
IQVNegative Net Change CNCNegative Net Change BTSGPositive Net Change
medical
3 Hospital Stocks Riding Strong Demand and Improved Efficiency
by Kaibalya Pravo Dey
The Zacks Medical-Hospital operators are benefiting from steady care demand while sharpening efficiency and portfolio strategy. Investors may want to track THC, ACHC and CYH.
THCPositive Net Change CYHPositive Net Change ACHCPositive Net Change
hospitals medical